IIAIGC study centre, 05401 Burlington, VT, USA.
Ann Pharm Fr. 2021 Sep;79(5):481-488. doi: 10.1016/j.pharma.2021.03.001. Epub 2021 Mar 6.
Over one hundred clinical trials since 2005 have failed to significantly improve the prognosis of glioblastoma. Since 2005, the standard of care has been maximal resection followed by 60Gy irradiation over six weeks with daily temozolomide. With this, a median survival of 2 years can be expected. This short paper reviewed how the pharmacodynamic attributes of an EMA/FDA approved, cheap, generic drug to treat pain, celecoxib, intersect with pathophysiological elements driving glioblastoma growth, such that growth drive inhibition can be expected from celecoxib. The two main attributes of celecoxib are carbonic anhydrase inhibition and cyclooxygenase-2 inhibition. Both attributes individually have been in active study as adjuncts during current cancer treatment, including that of glioblastoma. That research is briefly reviewed here. This paper concludes from the collected data, that starting celecoxib, 600 to 800mg twice daily before surgery and continuing it through the chemoirradiation phase of treatment would be a low-risk intervention with sound rationale.
自 2005 年以来，已有超过 100 项临床试验未能显著改善胶质母细胞瘤的预后。自 2005 年以来，标准治疗方法是最大限度地切除，然后在六周内进行 60Gy 的放射治疗，并每天服用替莫唑胺。采用这种方法，中位生存期可达到 2 年。本文简要回顾了一种已获欧洲药品管理局/美国食品药品监督管理局批准、廉价且通用的药物塞来昔布治疗疼痛的药效学特征如何与驱动胶质母细胞瘤生长的病理生理因素相互作用，从而可以预期塞来昔布能够抑制肿瘤生长。塞来昔布的两个主要特性是碳酸酐酶抑制和环氧化酶-2 抑制。这两个特性都曾作为辅助治疗在当前癌症治疗中进行过积极研究，包括胶质母细胞瘤的治疗。本文简要回顾了这方面的研究。本文从收集到的数据中得出结论，即在手术前开始服用塞来昔布，每天两次，每次 600 至 800 毫克，并在化疗和放疗阶段继续服用，这将是一种风险较低的干预措施，其理由充分。
